T cell receptors and immune therapy using the same

A method of treating a patient who has cancer, comprising administering to the patient a population of transformed CD8+ T cells expressing at least one vector encoding a T cell receptor (TCR),

• wherein the TCR comprises
• SEQ ID NO:
• 1, SEQ ID NO:
• 3, SEQ ID NO:
• 7 and SEQ ID NO:
• 9, or
• SEQ ID NO:
• 13, SEQ ID NO:
• 15, SEQ ID NO:
• 19 and SEQ ID NO:
• 21, or
• SEQ ID NO:
• 25, SEQ ID NO:
• 27, SEQ ID NO:
• 31 and SEQ ID NO:
• 33, or
• SEQ ID NO:
• 37, SEQ ID NO:
• 39, SEQ ID NO:
• 43 and SEQ ID NO:
• 45, or
• SEQ ID NO:
• 49, SEQ ID NO:
• 51, SEQ ID NO:
• 55 and SEQ ID NO:
• 57, or
• SEQ ID NO:
• 61, SEQ ID NO:
• 63, SEQ ID NO:
• 67 and SEQ ID NO:
• 69, or
• SEQ ID NO:
• 73, SEQ ID NO:
• 75, SEQ ID NO:
• 79 and SEQ ID NO:
• 81, or
• SEQ ID NO:
• 85, SEQ ID NO:
• 87, SEQ ID NO:
• 91 and SEQ ID NO:
• 93, or
• SEQ ID NO:
• 97, SEQ ID NO:
• 99, SEQ ID NO:
• 103 and SEQ ID NO:
• 105, or
• SEQ ID NO:
• 109, SEQ ID NO:
• 111, SEQ ID NO:
• 115 and SEQ ID NO:
• 117,
• wherein each of SEQ ID NOs:
• 1, 3, 7, 9, 13, 15, 19, 21, 25, 27, 31, 33, 37, 39, 43, 45, 49, 51, 55, 57, 61, 63, 67, 69, 73, 75, 79, 81, 85, 87, 91, 93, 97, 99, 103, 105, 109, 111, 115, and 117 comprise at most one conservative amino acid substitution,
• wherein the TCR is capable of binding to a peptide consisting of the amino acid sequence of KVLEYVIKV (SEQ ID NO:
• 133) in a complex with an MHC class I molecule, and
• wherein the cancer is selected from non-small cell lung cancer, small cell lung cancer, renal cell cancer, brain cancer, gastric cancer, colorectal cancer, hepatocellular cancer, head and neck cancer, pancreatic cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma, melanoma, ovarian cancer, urinary bladder cancer, uterine cancer, gallbladder and bile duct cancer, esophageal cancer.